| How many rare diseases are there? M Haendel, N Vasilevsky, D Unni, C Bologa, N Harris, H Rehm, ... Nature reviews drug discovery 19 (2), 77-78, 2020 | 366 | 2020 |
| DrugCentral 2021 supports drug discovery and repositioning S Avram, CG Bologa, J Holmes, G Bocci, TB Wilson, DT Nguyen, ... Nucleic acids research 49 (D1), D1160-D1169, 2021 | 168 | 2021 |
| TCRD and Pharos 2021: mining the human proteome for disease biology TK Sheils, SL Mathias, KJ Kelleher, VB Siramshetty, DT Nguyen, ... Nucleic Acids Research 49 (D1), D1334-D1346, 2021 | 130 | 2021 |
| ADME-Space: a new tool for medicinal chemists to explore ADME properties G Bocci, E Carosati, P Vayer, A Arrault, S Lozano, G Cruciani Scientific reports 7 (1), 6359, 2017 | 78 | 2017 |
| A machine learning platform to estimate anti-SARS-CoV-2 activities GB Kc, G Bocci, S Verma, MM Hassan, J Holmes, JJ Yang, S Sirimulla, ... Nature Machine Intelligence 3 (6), 527-535, 2021 | 66 | 2021 |
| Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19 G Bocci, SB Bradfute, C Ye, MJ Garcia, J Parvathareddy, W Reichard, ... ACS pharmacology & translational science 3 (6), 1278-1292, 2020 | 56 | 2020 |
| State of the art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references G Bocci, TI Oprea, LZ Benet The AAPS Journal 24 (2), 37, 2022 | 44 | 2022 |
| How to illuminate the druggable genome using pharos T Sheils, SL Mathias, VB Siramshetty, G Bocci, CG Bologa, JJ Yang, ... Current protocols in bioinformatics 69 (1), e92, 2020 | 36 | 2020 |
| Side-chain modified ergosterol and stigmasterol derivatives as liver X receptor agonists M Marinozzi, FF Castro Navas, D Maggioni, E Carosati, G Bocci, ... Journal of Medicinal Chemistry 60 (15), 6548-6562, 2017 | 30 | 2017 |
| Cyto-and enzyme toxicities of ionic liquids modelled on the basis of VolSurf+ descriptors and their principal properties A Paternō, G Bocci, G Cruciani, CG Fortuna, L Goracci, S Scire, ... SAR and QSAR in Environmental Research 27 (3), 221-244, 2016 | 20 | 2016 |
| GLUT3 inhibitor discovery through in silico ligand screening and in vivo validation in eukaryotic expression systems CV Iancu, G Bocci, M Ishtikhar, M Khamrai, M Oreb, TI Oprea, J Choe Scientific Reports 12 (1), 1429, 2022 | 17 | 2022 |
| New insights in the in vitro characterisation and molecular modelling of the P-glycoprotein inhibitory promiscuity G Bocci, A Moreau, P Vayer, C Denizot, O Fardel, Y Parmentier European Journal of Pharmaceutical Sciences 121, 85-94, 2018 | 17 | 2018 |
| Modelling the aquatic toxicity of ionic liquids by means of VolSurf in silico descriptors A Paternō, G Bocci, L Goracci, G Musumarra, S Scirč SAR and QSAR in Environmental Research 27 (1), 1-15, 2016 | 17 | 2016 |
| Combining machine learning and quantum mechanics yields more chemically aware molecular descriptors for medicinal chemistry applications S Tortorella, E Carosati, G Sorbi, G Bocci, S Cross, G Cruciani, L Storchi Journal of Computational Chemistry 42 (29), 2068-2078, 2021 | 9 | 2021 |
| Supervised learning with word embeddings derived from PubMed captures latent knowledge about protein kinases and cancer V Ravanmehr, H Blau, L Cappelletti, T Fontana, L Carmody, B Coleman, ... NAR Genomics and Bioinformatics 3 (4), lqab113, 2021 | 8 | 2021 |
| Can BDDCS illuminate targets in drug design? G Bocci, LZ Benet, TI Oprea Drug discovery today 24 (12), 2299-2306, 2019 | 6 | 2019 |
| Prediction of Ligand Activity at Subcellular Location M Varshney, S Verma, G KC, G Bocci, TI Oprea, S Sirimulla | | 2021 |
Tudor OpreaCEO, Expert Systems IncVerifierad e-postadress på expertsystems.inc
